Prostate Cancer

Second Multicenter GVAX Phase I/II Trial Initiated

Published in Vaccine Weekly, April 19th, 1999

Cell Genesys, Inc., Foster City, California, announced that it has initiated a second multicenter, Phase I/II clinical trial of GVAX cancer vaccine for prostate cancer in approximately 40 patients who have failed hormone therapy for their prostate cancer.

The trial is in addition to a multicenter, Phase I/II trial which began in December 1998 and enrolls approximately 40 earlier stage patients who have not yet received hormone therapy. Both of these expanded trials were prompted by encouraging results in the initial study of GVAX prostate cancer vaccine conducted in 1998 which demonstrated that the treatment was safe and well-tolerated and resulted in antitumor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry